Dostarlimab: A breakthrough in the field of oncology
Open Access
- 5 July 2022
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Medicine & Surgery
- Vol. 80, 104046
- https://doi.org/10.1016/j.amsu.2022.104046
Abstract
Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of cancer treatment facilities in third-world countries like Pakistan where a sig-nificant prevalence of CRC has been detected. The five FDA-approved drugs used for CCR therapy (Durvalumab, Atezolizumab, Nivolumab, Pembrolizumab, and Avelumab) have been associated with a high occurrence of grade 3-4 adverse side effects. Dostarlimab is a new drug previously used to treat endometrial cancers and has a mechanism of action that is in accordance with other PD-1/PD-L1 inhibitors. A recent clinical trial has found Dostarlimab to cure 100% of the CRC patients who were given this drug while also showing no adverse events of grade 3 or higher in any patient. The recent clinical trial has opened up doors for future clinical trials perhaps with bigger sample sizes and ones that also include CRC patients belonging to wider geo-economic backgrounds such as those of Pakistan and other Asian countries.Keywords
This publication has 14 references indexed in Scilit:
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerThe New England Journal of Medicine, 2020
- A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal CancerCancer Research and Treatment, 2020
- A review of access to cancer facilities in Punjab, PakistanCancer Reports, 2020
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trialThe Lancet Oncology, 2019
- Immunotherapy in colorectal cancer: rationale, challenges and potentialNature Reviews Gastroenterology & Hepatology, 2019
- Population/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trialsBritish Journal of Clinical Pharmacology, 2019
- Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapyPharmacology & Therapeutics, 2018
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010